Inmune Bio

INMB Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

CORDStrom/Ebstrocel MAA filing2H 2026CORDStrom/Ebstrocel MAA filing, 2H 2026, major
CORDStrom/Ebstrocel manufacturing update2H 2026CORDStrom/Ebstrocel manufacturing update, 2H 2026, notable
CORDStrom/Ebstrocel BLA filinglate 2026CORDStrom/Ebstrocel BLA filing, late 2026, material
CORDStrom/Ebstrocel EU decision2027CORDStrom/Ebstrocel EU decision, 2027, thesis-defining
INMB corporate financingmid-2027INMB corporate financing, mid-2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

CORDStrom

Ebstrocel

Cell Target: COL7A1

Recessive Dystrophic Epidermolysis Bullosa intravenous Great Ormond Street Hospital for Children NHS Foundation Trust

INKmune

INB-16

Cell Target: NK cells

Metastatic Castrate-Resistant Prostate Cancer Phase 2 intravenous NCT06056791

Technology platforms

CORDStrom

Proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (MSC) platform engineered to address donor variability and manufacturing inconsistency. Lead product Ebstrocel™ targets recessive dystrophic epidermolysis bullosa (RDEB); platform expansion targets include osteoarthritis, pulmonary disease, oncology, and other inflammatory or tissue-repair indications. Transitioning to regulatory filing phases with MAA planned for UK MHRA in 2026, EU EMA in 2027, and U.S. BLA submission planned early 2027.

DN-TNF · Xencor

Dominant negative tumor necrosis factor variant protein platform covering pegylated DN-TNF variants XPro1595 and INB03; targets neuroinflammation via selective neutralization of soluble TNF; focus on neurodegenerative diseases including Alzheimer's disease

Targets: soluble TNF, sTNF

CORDStrom · Anthony Nolan Cord Blood Bank

Proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address donor variability and manufacturing inconsistency; focus area: rare pediatric skin diseases including RDEB, with plans to expand into additional disease-specific cell therapies.

XPro1595

Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform selectively neutralizing soluble TNF to eliminate neuroinflammation; focus areas: early Alzheimer's disease and oncology (HER2-positive breast cancer brain metastases).

Targets: soluble TNF, TNF

Discontinued (2)

XPro — Alzheimer's Disease · Phase 2 trial failed to meet primary endpoint; halted immediate plans to develop XPro for Alzheimer's or other indications due to insufficient resources; seeking a partner
INKmune — Myelodysplastic Syndrome · terminated further enrollment in the MDS/AML trial in March 2024 due to post-Covid recruitment problems

Biotech Distilled coverage (2)

2026-08-07 UPDATE: INmune Bio (INMB) - The Quarter That Bought Time, Not Runway
2026-07-21 INmune Bio (INMB) — Scientific Deep Dive for CORDStrom (Ebstrocel) and XPro1595, Plus the DN-TNF & NK Pipeline 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.